Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of OSAHS Hypoxia Indicators with Early Renal Injury and Serum Fibroblast Growth Factor 21 in Obese Type 2 Diabetic Patients.
|
31172456 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the results of the present study revealed a new mechanism underlying the regulation of hepatic ER stress and FGF21 expression induced by EPO; thus, EPO may be considered as a potential therapeutic agent for the treatment of fatty liver and obesity.
|
31173165 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of FGF21 and decreased levels of adiponectin in obesity indicate FGF21-adiponectin axis dysfunction.
|
30978696 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study assessed pegbelfermin (BMS-986036), recombinant PEGylated human fibroblast growth factor 21 (FGF21), in patients with obesity and T2DM predisposed to fatty liver.
|
30520566 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among those browning agents reported recently, FGF21 play as a quite promising candidate for treating obesity for its obvious enhancement of thermogenic capacity in adipocyte and significant improvement of metabolic disorders in both mice and human.
|
30496126 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus.
|
30991048 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review will cover the complexities in FGF21 biology in rodents and humans, with emphasis on its role in protection from central and peripheral facets of obesity.
|
31248786 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of FGF21 deficiency on obesity-induced hypothalamic inflammation and thermogenic responses.
|
30863887 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data indicate that glucolipotoxicity-induced FGF21 activation mediates islet autophagy via AMPK inhibition, and further consolidate the evidence for the FGF21/analog being a pharmacotherapeutic target for obesity and its related T2DM.
|
31121855 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, plasma FGF21 levels are paradoxically increased in type 2 diabetes mellitus (T2DM) and obesity, suggesting resistance to this ligand.
|
31798902 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of FGF21 deficiency on obesity-induced skeletal muscle inflammation and atrophy in mice.
|
31312114 |
2019 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results The T allele of rs11665896 in the FGF21 gene was associated with obesity (odds ratio [OR] = 1.99, 95% confidence interval [CI] = 1.14-3.46; p = 0.0151).
|
31323006 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, treatment with FGF21 could obviously reverse NAFLD and synergistically alleviate obesity and counteract insulin resistance.
|
31419414 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Besides, serum levels of FGF21 increase in various diseases including in diabetes mellitus, hypertension, and obesity, which may be related to initiating and exacerbating atherosclerosis.
|
30879171 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this review we focus on circulating FGF21 levels in humans and their associations with disease and clinical parameters, focusing primarily on obesity and obesity-associated diseases such as type-2 diabetes.
|
31108554 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cross-sectional associations were observed between IHTG and IGF1 (β = -0.51; 95% CI, -0.82 to -0.20), IGFBP1 (β = -4.2; 95% CI, -7.7 to -0.7), and FGF21 (β = 2.1; 95% CI, 1.3 to 2.9) in lean men and men with abdominal obesity combined.
|
30753672 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In humans, circulating FGF21 levels are increased in insulin-resistant morbidities such as obesity and type 2 diabetes mellitus (T2DM).
|
30346647 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
|
30848827 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The data demonstrate an important AHR-FGF21 regulatory axis that influences adipose biology and may represent a "druggable" therapeutic target for obesity and its related metabolic disorders.
|
30813227 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH.
|
30893110 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Maresin 1 Regulates Hepatic FGF21 in Diet-Induced Obese Mice and in Cultured Hepatocytes.
|
31576649 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In recent clinical trials, an FGF21 analogue reduced insulin levels and body weight, and ameliorated dyslipidemia in patients with type 2 diabetes mellitus and obesity, all of which are well-known risk factors for kidney disease.
|
29108880 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results obtained by ELISA and real-time polymerase chain reaction showed that FGF-21 efficiently ameliorated obesity-related inflammation in MSG-obesity mice.
|
30703283 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Fibroblast Growth Factor 21 (FGF21) is considered an attractive therapeutic target for obesity and obesity-related disorders due to its beneficial effects in lipid and carbohydrate metabolism.
|
31546675 |
2019 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum FGF21 levels were significantly higher in obesity and type 2 diabetes mellitus (T2DM) populations.
|
31582974 |
2019 |